What I would really like to know is why use the margolis classification. Seems like very old literature and poorly done retrospective. Doesn’t give any indication of difficult to treat really and especially based on this study they have debunked the margolis classification.
Now I’m not a vascular physician or surgeon and i would have to look at the literature on it but surely there should be a more up to date classification.
In my opinion the study failed because of a number of reasons.
1. The actual screened patients were the wrong patients (inappropriate classification)
2. VF001 may actually have no effect
3. They never compared against community care as a control arm.
I have also moved on and hold no grudges against management other than they just flushed a potentially lucrative company and shareholders wealth down the toilet.
I still hold and wait for the future direction of the company which may turn around over a couple of months to years.
- Forums
- ASX - By Stock
- Procedural Mistakes or lack of public information's in reference to the EU andFDA Trial
What I would really like to know is why use the margolis...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add FTT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
NXD
NEXTED GROUP LIMITED
Nick Poll, Managing Director
Nick Poll
Managing Director
SPONSORED BY The Market Online